OP2 Drugs

OP2 Drugs was a French biotechnology company founded in 2015 and based in Pessac, France. The company specialized in the development of innovative therapies for cardiovascular and neurological conditions, with a primary focus on reducing myocardial infarct size and preventing the 'no-reflow' phenomenon following a heart attack. Its lead candidate, OP2113 (anethole trithione), was a repurposed small molecule designed to modulate mitochondrial reactive oxygen species (mtROS) and protect tissues from ischemia-reperfusion injury. Despite raising over $4 million in funding and establishing academic collaborations with institutions like the University of Bordeaux and HMRI, the company entered liquidation in late 2022. OP2 Drugs operated on a drug repurposing model, leveraging existing safety data for molecules to accelerate development in new indications.